SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-9

acquisitionAnnounced · Feb 23, 2026BiotechnologySource · CredibleArticle · Factual

Arcellx · Gilead Sciences

Gilead Sciences acquires Arcellx

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$7.8B

Target

Arcellx

NASDAQ: ACLX · Redwood City, California

Acquirer

Gilead Sciences

Full Acquisition

Status

Pending

Gilead Sciences agreed to acquire Arcellx. Reported deal value: $7.8B. Status: Pending. Sector: Biotechnology. Target headquarters context: Redwood City, California, United States.

This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.

Today at 9:45 AM Gilead Sciences To Acquire Arcellx In $7.8 Billion Deal To Strengthen Cell Therapy Portfolio Gilead Sciences announced it has entered into a definitive agreement to acquire Arcellx , Inc. for $115 per share in cash plus one contingent value right of $5 per share, representing an implied equity value of $7.8 billion payable at closing

Deal timeline

Announced

Feb 23, 2026 · pulse2.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in Biotechnology with a reported deal value of $7.8B. Figures and status may change as sources update.

Sources: pulse2.com · Primary article · FireStrike proprietary index